Certain Radio Frequency Micro-Needle Dermatological Treatment Devices and Components Thereof; Commission Determination Not To Review an Initial Determination Terminating the Investigation in Its Entirety Based on a Settlement Agreement; Termination of the Investigation, 54175 [2019-21981]

Download as PDF Federal Register / Vol. 84, No. 196 / Wednesday, October 9, 2019 / Notices Issued: October 4, 2019. Lisa Barton, Secretary to the Commission. [FR Doc. 2019–22058 Filed 10–8–19; 8:45 am] BILLING CODE 7020–02–P INTERNATIONAL TRADE COMMISSION [Investigation No. 337–TA–1112] Certain Radio Frequency Micro-Needle Dermatological Treatment Devices and Components Thereof; Commission Determination Not To Review an Initial Determination Terminating the Investigation in Its Entirety Based on a Settlement Agreement; Termination of the Investigation U.S. International Trade Commission. ACTION: Notice. AGENCY: Notice is hereby given that the U.S. International Trade Commission has determined not to review an initial determination (‘‘ID’’) (Order No. 45) of the presiding administrative law judge (‘‘ALJ’’) terminating the investigation as to the remaining respondents, EndyMed Medical Inc. of New York City, New York and EndyMed Medical Ltd. of Caesarea, Israel (‘‘Endy’’), based on a settlement agreement. The investigation is terminated. FOR FURTHER INFORMATION CONTACT: Clint Gerdine, Esq., Office of the General Counsel, U.S. International Trade Commission, 500 E Street SW, Washington, DC 20436, telephone (202) 708–2310. Copies of non-confidential documents filed in connection with this investigation are or will be available for inspection during official business hours (8:45 a.m. to 5:15 p.m.) in the Office of the Secretary, U.S. International Trade Commission, 500 E Street SW, Washington, DC 20436, telephone (202) 205–2000. General information concerning the Commission may also be obtained by accessing its internet server at https://www.usitc.gov. The public record for this investigation may be viewed on the Commission’s electronic docket (EDIS) at https:// edis.usitc.gov. Hearing-impaired persons are advised that information on this matter can be obtained by contacting the Commission’s TDD terminal on (202) 205–1810. SUPPLEMENTARY INFORMATION: The Commission instituted this investigation on May 15, 2018, based on a complaint filed on behalf of Syneron Medical Ltd. of Yokneam Illit, Israel; Candela Corporation of Wayland, Massachusetts; khammond on DSKJM1Z7X2PROD with NOTICES SUMMARY: VerDate Sep<11>2014 17:13 Oct 08, 2019 Jkt 250001 and Massachusetts General Hospital of Boston, Massachusetts. 83 FR 22515–16 (May 15, 2018). The complaint, as supplemented, alleges violations of section 337 of the Tariff Act of 1930, as amended, 19 U.S.C. 1337, based upon the importation into the United States, the sale for importation, and the sale within the United States after importation of certain radio frequency micro-needle dermatological treatment devices and components thereof by reason of infringement of certain claims of U.S. Patent Nos. 9,510,899 (‘‘the ’899 patent’’) and 9,095,357. The Commission’s notice of investigation named several respondents including Endy; Invasix, Inc. and Inmode Md, Ltd. of Lake Forest, California; Lumenis Ltd. and Invasix, Ltd. of Yokneam, Israel; Ilooda Co., Ltd. and Lutronic Corp. of Gyeonggi-do, Republic of Korea; Cutera, Inc. of Brisbane, California; Emvera Technologies, LLC of Cedartown, California; Rohrer Aesthetics, LLC of Homewood, Alabama; Lutronic, Inc. of Billerica, Massachusetts; Sung Hwan E&B Co., Ltd. d/b/a SHEnB Co., Ltd. and Jeisys Medical, Inc. of Seoul, Republic of Korea; Aesthetics Biomedical, Inc. of Phoenix, Arizona; Cartessa Aesthetics of Hockessi, Delaware; Perigee Medical Center LLC of Tracy, California; and Pollogen, Ltd. of Tel Aviv-Jaffa, Israel. The Office of Unfair Import Investigations is not participating in the investigation. All other respondents have been terminated from the investigation based on settlement agreement. See Order No. 43 (July 23, 2019), unreviewed by Comm’n Notice (Aug. 13, 2019); Order No. 23 (April 9, 2019), unreviewed by Comm’n Notice (May 7, 2019); Order No. 20 (Mar. 26, 2019), unreviewed by Comm’n Notice (Apr. 16, 2019); Order No. 18 (Mar. 20, 2019), unreviewed by Comm’n Notice (Apr. 11, 2019); Order No. 16 (Mar. 6, 2019), unreviewed by Comm’n Notice (Mar. 27, 2019); Order No. 15 (Feb. 22, 2019), unreviewed by Comm’n Notice (Mar. 21, 2019). On September 4, 2019, Complainants and Endy jointly moved to terminate the investigation based on a settlement agreement. On September 11, 2019, the ALJ issued the subject ID (Order No. 45), granting the joint motion terminating the investigation in its entirety based on settlement agreement. She found that the motion for termination satisfied Commission Rule 210.21, 19 CFR 210.21, and that termination of the investigation is not contrary to the public interest. No party petitioned for review. PO 00000 Frm 00074 Fmt 4703 Sfmt 4703 54175 The Commission has determined not to review the subject ID. The investigation is terminated. The authority for the Commission’s determination is contained in section 337 of the Tariff Act of 1930, as amended, 19 U.S.C. 1337, and in Part 210 of the Commission’s Rules of Practice and Procedure, 19 CFR part 210. By order of the Commission. Issued: October 3, 2019. Lisa Barton, Secretary to the Commission. [FR Doc. 2019–21981 Filed 10–8–19; 8:45 am] BILLING CODE 7020–02–P DEPARTMENT OF JUSTICE [CPCLO Order No. 010–2019] Privacy Act of 1974; System of Records Federal Bureau of Investigation, United States Department of Justice. ACTION: Notice of a Modified System of Records. AGENCY: Pursuant to the Privacy Act of 1974 and Office of Management and Budget (OMB) Circular No. A–108, notice is hereby given that the Federal Bureau of Investigation (FBI), a component within the United States Department of Justice (DOJ or Department), proposes to modify a system of records notice titled the National Instant Criminal Background Check System (NICS), JUSTICE/FBI– 018. The FBI proposes to consolidate and replace the following previous SORNs related to NICS: ‘‘National Instant Criminal Background Check System/FBI–018,’’ published at 63 FR 65223 (Nov. 25, 1998), 65 FR 78190 (Dec. 14, 2000), 66 FR 6676 (Jan. 22, 2001), 66 FR 8425 (Jan. 31, 2001), 66 FR 12959 (Mar. 1, 2001), and 82 FR 24147 (May 25, 2017). This notice also updates the ‘‘PURPOSE(S) OF THE SYSTEM,’’ ‘‘CATEGORIES OF INDIVIDUALS COVERED BY THE SYSTEM,’’ ‘‘CATEGORIES OF RECORDS IN THE SYSTEM,’’ and ‘‘ROUTINE USES OF RECORDS MAINTAINED IN THE SYSTEM, INCLUDING CATEGORIES OF USERS AND THE PURPOSES OF SUCH USES’’ of the SORN. DATES: In accordance with 5 U.S.C. 552a(e)(4) and (11), the public has 30 days in which to comment on the routine uses, described below. Therefore, please submit any comments by November 8, 2019. ADDRESSES: The public, OMB, and Congress are invited to submit any SUMMARY: E:\FR\FM\09OCN1.SGM 09OCN1

Agencies

[Federal Register Volume 84, Number 196 (Wednesday, October 9, 2019)]
[Notices]
[Page 54175]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-21981]


-----------------------------------------------------------------------

INTERNATIONAL TRADE COMMISSION

[Investigation No. 337-TA-1112]


Certain Radio Frequency Micro-Needle Dermatological Treatment 
Devices and Components Thereof; Commission Determination Not To Review 
an Initial Determination Terminating the Investigation in Its Entirety 
Based on a Settlement Agreement; Termination of the Investigation

AGENCY: U.S. International Trade Commission.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Notice is hereby given that the U.S. International Trade 
Commission has determined not to review an initial determination 
(``ID'') (Order No. 45) of the presiding administrative law judge 
(``ALJ'') terminating the investigation as to the remaining 
respondents, EndyMed Medical Inc. of New York City, New York and 
EndyMed Medical Ltd. of Caesarea, Israel (``Endy''), based on a 
settlement agreement. The investigation is terminated.

FOR FURTHER INFORMATION CONTACT: Clint Gerdine, Esq., Office of the 
General Counsel, U.S. International Trade Commission, 500 E Street SW, 
Washington, DC 20436, telephone (202) 708-2310. Copies of non-
confidential documents filed in connection with this investigation are 
or will be available for inspection during official business hours 
(8:45 a.m. to 5:15 p.m.) in the Office of the Secretary, U.S. 
International Trade Commission, 500 E Street SW, Washington, DC 20436, 
telephone (202) 205-2000. General information concerning the Commission 
may also be obtained by accessing its internet server at https://www.usitc.gov. The public record for this investigation may be viewed 
on the Commission's electronic docket (EDIS) at https://edis.usitc.gov. 
Hearing-impaired persons are advised that information on this matter 
can be obtained by contacting the Commission's TDD terminal on (202) 
205-1810.

SUPPLEMENTARY INFORMATION: The Commission instituted this investigation 
on May 15, 2018, based on a complaint filed on behalf of Syneron 
Medical Ltd. of Yokneam Illit, Israel; Candela Corporation of Wayland, 
Massachusetts; and Massachusetts General Hospital of Boston, 
Massachusetts. 83 FR 22515-16 (May 15, 2018). The complaint, as 
supplemented, alleges violations of section 337 of the Tariff Act of 
1930, as amended, 19 U.S.C. 1337, based upon the importation into the 
United States, the sale for importation, and the sale within the United 
States after importation of certain radio frequency micro-needle 
dermatological treatment devices and components thereof by reason of 
infringement of certain claims of U.S. Patent Nos. 9,510,899 (``the 
'899 patent'') and 9,095,357. The Commission's notice of investigation 
named several respondents including Endy; Invasix, Inc. and Inmode Md, 
Ltd. of Lake Forest, California; Lumenis Ltd. and Invasix, Ltd. of 
Yokneam, Israel; Ilooda Co., Ltd. and Lutronic Corp. of Gyeonggi-do, 
Republic of Korea; Cutera, Inc. of Brisbane, California; Emvera 
Technologies, LLC of Cedartown, California; Rohrer Aesthetics, LLC of 
Homewood, Alabama; Lutronic, Inc. of Billerica, Massachusetts; Sung 
Hwan E&B Co., Ltd. d/b/a SHEnB Co., Ltd. and Jeisys Medical, Inc. of 
Seoul, Republic of Korea; Aesthetics Biomedical, Inc. of Phoenix, 
Arizona; Cartessa Aesthetics of Hockessi, Delaware; Perigee Medical 
Center LLC of Tracy, California; and Pollogen, Ltd. of Tel Aviv-Jaffa, 
Israel. The Office of Unfair Import Investigations is not participating 
in the investigation. All other respondents have been terminated from 
the investigation based on settlement agreement. See Order No. 43 (July 
23, 2019), unreviewed by Comm'n Notice (Aug. 13, 2019); Order No. 23 
(April 9, 2019), unreviewed by Comm'n Notice (May 7, 2019); Order No. 
20 (Mar. 26, 2019), unreviewed by Comm'n Notice (Apr. 16, 2019); Order 
No. 18 (Mar. 20, 2019), unreviewed by Comm'n Notice (Apr. 11, 2019); 
Order No. 16 (Mar. 6, 2019), unreviewed by Comm'n Notice (Mar. 27, 
2019); Order No. 15 (Feb. 22, 2019), unreviewed by Comm'n Notice (Mar. 
21, 2019).
    On September 4, 2019, Complainants and Endy jointly moved to 
terminate the investigation based on a settlement agreement.
    On September 11, 2019, the ALJ issued the subject ID (Order No. 
45), granting the joint motion terminating the investigation in its 
entirety based on settlement agreement. She found that the motion for 
termination satisfied Commission Rule 210.21, 19 CFR 210.21, and that 
termination of the investigation is not contrary to the public 
interest. No party petitioned for review.
    The Commission has determined not to review the subject ID. The 
investigation is terminated.
    The authority for the Commission's determination is contained in 
section 337 of the Tariff Act of 1930, as amended, 19 U.S.C. 1337, and 
in Part 210 of the Commission's Rules of Practice and Procedure, 19 CFR 
part 210.

    By order of the Commission.

    Issued: October 3, 2019.
Lisa Barton,
Secretary to the Commission.
[FR Doc. 2019-21981 Filed 10-8-19; 8:45 am]
 BILLING CODE 7020-02-P